• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Vaccine biotech Icosavax sets terms for $150 million IPO

firstwordpharmaJuly 23, 2021

Tag: Icosavax , Vaccine , IPO

Icosavax plans to raise $150 million in its initial public offering by offering 10 million shares at a price range of $14 to $16, as reported by NASDAQ.

The company is developing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life threatening respiratory diseases. 

Icosavax’s lead program is IVX-A12, a bivalent candidate targeting both respiratory syncytial virus and human metapneumovirus.


Previous:AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

Next:Guidelines Updated for Treatment of Sexually Transmitted Infections

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Vaccine biotech Icosavax sets terms for $150 million IPO | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Hualan- Influenza Vaccine

Hualan- Influenza Vaccine
Nanoliposomal CCA

Nanoliposomal CCA
Recombinant Hepatitis E vaccine

Recombinant Hepatitis E vaccine
Tripotassium phosphate(TKP)

Tripotassium phosphate(TKP)
Hualan bio Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological

Hualan bio Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological
STPP(Sodium Tripolyphosphate)

STPP(Sodium Tripolyphosphate)
Recombinant Hepatitis B Vaccine (Hansenula polymorpha)

Recombinant Hepatitis B Vaccine (Hansenula polymorpha)
Liposomal [6]-PARADOL

Liposomal [6]-PARADOL
Hualan Influenza Vaccine

Hualan Influenza Vaccine
Alpha Lipoic Acid

Alpha Lipoic Acid

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service